John Morgan, MD, PhD

John Morgan, MD, PhD

Professor and Director
Movement & Memory Disorder Programs
Department of Neurology
Medical College of Georgia
Augusta University
Augusta, Georgia

Related Videos

What is the starting dose of CD/LD, and what is the range of CD/LD formulations available for PD? Why does the eventual onset of motor fluctuations and “wearing off” observed over time present opportunities for scored, fractionated dose formulations? Video

What is the starting dose of CD/LD, and what is the range of CD/LD formulations available for PD? Why does the eventual onset of motor fluctuations and “wearing off” observed over time present opportunities for scored, fractionated dose formulations?

What is the initial starting dose of carbidopa/levodopa, and what is the range of CD/LD formulations currently available for PD? Why does the eventual onset of motor fluctuations and “wearing off” observed over time present opportunities ...

What makes the scored, fractionated formulation of CD/LD different from other tablets and what group of patients should be considered appropriate candidates for treatment with this titratable treatment for PD? Video

What makes the scored, fractionated formulation of CD/LD different from other tablets and what group of patients should be considered appropriate candidates for treatment with this titratable treatment for PD?

What makes the scored, fractionated formulation of CD/LD different from other tablets and what group of patients should be considered appropriate candidates for treatment with this titratable treatment for PD?

What formulations for CD/LD are approved and available for PD, and for once a person with PD begins to experience significant “off time” on CD/LD. What is your approach to minimizing deterioration in clinical symptoms? Video

What formulations for CD/LD are approved and available for PD, and for once a person with PD begins to experience significant “off time” on CD/LD. What is your approach to minimizing deterioration in clinical symptoms?

What formulations for CD/LD are approved and available for PD, and for once a person with PD begins to experience significant “off time” on CD/LD. What is your approach to minimizing deterioration in clinical symptoms?

If you embark on a therapeutic transition from standard CD/LD to the scored, fractionable dosing formulation of CD/LD, exactly how do you advise or counsel the patient on a titration plan? Video

If you embark on a therapeutic transition from standard CD/LD to the scored, fractionable dosing formulation of CD/LD, exactly how do you advise or counsel the patient on a titration plan?

If you embark on a therapeutic transition from standard CD/LD to the scored, fractionable dosing formulation of CD/LD, exactly how do you advise or counsel the patient on a titration plan?

Can you summarize your current treatment algorithm for treating “off time?” Video

Can you summarize your current treatment algorithm for treating “off time?”

Can you summarize your current treatment algorithm for treating “off time?”

Can you share a person you have managed who has experienced increased “off time” and motor fluctuations with CD/LD who might be an ideal patient for treatment with titratable formulations, including those based on scored, fractionable doses of CD/LD? Video

Can you share a person you have managed who has experienced increased “off time” and motor fluctuations with CD/LD who might be an ideal patient for treatment with titratable formulations, including those based on scored, fractionable doses of CD/LD?

Can you share a person you have managed who has experienced increased “off time” and motor fluctuations with CD/LD who might be an ideal patient for treatment with titratable formulations, including those based on scored, fractionable doses of CD/LD?

Dr. Morgan, we’re pleased to have you presenting on this program on new advances and formulations of CD/LD with a special focus on “off time.” Can you provide us with a summary of topics you will cover on today’s CME program? Video

Dr. Morgan, we’re pleased to have you presenting on this program on new advances and formulations of CD/LD with a special focus on “off time.” Can you provide us with a summary of topics you will cover on today’s CME program?

Dr. Morgan, we’re pleased to have you presenting on this program on new advances and formulations of CD/LD with a special focus on “off time.” Can you provide us with a summary of topics you will cover on today’s CME program?